Abstract: The present disclosure provides a co-formulation that includes an antibody that binds specifically to C5 and a C5 iRNA which is a glycoconjugate that includes a ligand having terminal N-Acetylgalactosamine (GalNAc) residues and/or N-acetylglucosamine (GlcNAc) residues. Methods for reducing degradation of glycoconjugate RNA by beta-hexosaminidase enzyme are also provided. The present disclosure also includes methods for treating or preventing a C5-associated disease or disorder by administering one or more doses of an anti-C5 antibody or antigen-binding fragment thereof in combination with one or more doses of a C5 iRNA; preferably wherein the anti-C5 antibody or fragment and the C5 iRNA are in a co-formulation. The present disclosure also includes dosing regimens for treating C5-associated disease or disorder with a combination of anti-C5 antibody and C5 iRNA in subjects that either are treatment naïve or are switching from a previous C5 inhibitor therapy.

Abstract: A fault detection method, includes the following steps. A target sequence is received, the target sequence includes several data. A first moving average operation is performed on the target sequence to establish a first moving average sequence. A second moving average operation is performed on the target sequence to establish a second moving average sequence. A difference operation between the first moving average sequence and the second moving average sequence is performed to obtain a difference sequence, the difference sequence includes several difference values. An upper limit value is set. When one of the difference values is greater than the upper limit value, the target sequence is determines as abnormal.

Abstract: The present application disclose a method and a device for detecting and correcting abnormal scoring of peer reviews, which includes: converting collected scoring data into a two-dimensional matrix and preprocessing the data; determining the anomaly of the processed structured data with a one-way anomaly detection method, a consistency check method and a two-way anomaly detection method, and classifying the detected abnormal data into an abnormal data set; repairing the abnormal data for the abnormal data set with an information entropy correction method; generating an ability evaluation report according to the abnormal data set, performing weighed averaging on the corrected scoring data according to the scoring weights of reviewers in the ability evaluation report to obtain a final scoring result, and generating an abnormal scoring correction report. The present application can effectively detect the abnormal phenomenon of peer reviews in the performance appraisal of enterprise personnel.

Abstract: The general inventive concepts are based on the discovery that mammalian fertility and embryo development can be enhanced by a CHK1 inhibitor. A method for treating human infertility is disclosed. The method comprises identification of an individual having altered CHK1 function and administering a therapeutically effective amount of a CHK1 inhibitor. Further, embryonic development can be enhanced by the use of a culture medium comprising CHK1 inhibitor.

Abstract: A curable polyolefin composition is provided. The curable polyolefin composition comprises: (A) a polyolefin having at least two aliphatic unsaturated bonds per molecule and having a viscosity at 25° C. of less than 2,500 mPa·s; (B) an organopolysiloxane having at least two silicon atom-bonded hydrogen atoms per molecule; (C) a hydrosilylation reaction catalyst; and (D) a thermal conductive filler. The curable polyolefin composition can be cured to form a soft material with good thermal conductive properties.

Abstract: This invention is directed to, inter alia, stable cartilage-derived progenitor cell lines as well as methods for producing stable cartilage-derived progenitor cell lines from diseased human cartilaginous tissues and lesions. Also provided herein are methods for using cartilage-derived progenitor cell lines for treatment of cartilage and bone degenerative diseases.

Abstract: Provided herein is a method for preparing a flat-surfaced MAPbBr3 perovskite block and a use thereof. The preparation steps include: preparing a mixed solution formed by adding MABr and PbBr2 to a DMF solution; preparing a nickel foam mesh with the precursor solution; removing excess reaction liquid from the nickel foam mesh; and drying the nickel foam mesh to obtain the flat-surfaced MAPbBr3 perovskite block. It employs a solution-based method to fabricate MAPbBr3 perovskite on a nickel foam mesh, resulting in flat-surfaced MAPbBr3 perovskite blocks. The prepared perovskite can be utilized in the fields of solar cells, LEDs, and photoelectric hydrolysis. The method is simple and easy to operate, by using a solution-based method on a nickel foam mesh, flat-surfaced perovskite blocks can be formed, and the flat surface is beneficial for light absorption and energy conversion, thus enhancing the performance of the sample.

Abstract: A method for producing a carotenoid or apocarotenoid is disclosed. The method comprises the step of expressing in a host cell an expression module comprising an expression vector having a coding region encoding at least one optimised carotenoid or apocarotenoid generating enzyme, the coding region being operably linked to a promoter. A host cell comprising an expression vector having a coding region encoding at least one optimised carotenoid or apocarotenoid generating enzyme, the coding region being operably linked to a promoter is also provided together with a kit.

Abstract: The present invention relates to a winch clutch and a winch thereof. The winch clutch comprises a first gear ring, a drive motor, a rotary member, a transmission member, a clutching member and an elastic reset member. The clutching member is separably connected to the plurality of clutch portions of the first gear ring to stop the first gear ring. Compared with the prior art, the winch clutch of the present invention uses the drive motor to drive the rotary member to rotate, and achieves connection or separation between the clutching member and the clutch portions on the first gear ring through the transmission member, so as to control the winch to start or stop. Compared with conventional manual clutches, manual operation is not required and operation is convenient in the present invention, completely solving the problem of a failure of a vehicle winch clutch.

Abstract: A composite film includes a first thermoplastic elastomer film layer and a second thermoplastic elastomer film layer, wherein the first thermoplastic elastomer film layer includes a first styrenic block copolymer. The second thermoplastic elastomer film layer is disposed on the first thermoplastic elastomer film layer, wherein the second thermoplastic elastomer film layer includes a second styrenic block copolymer, diffusion particles dispersed in the second thermoplastic elastomer film layer, and a surface microstructure disposed on the surface of the second thermoplastic elastomer film layer.

Abstract: A nitrogen-containing polycyclic fused ring compound represented by formula I, a pharmaceutical composition thereof, a preparation method therefor, and a use thereof are provided. The compound has an inhibitory effect on RET gatekeeper residue mutant RET V804M mutation, RET solvent front residue mutant G810R, and other clinically relevant RET mutants and RET-wt. The compound can also significantly inhibit the growth of a TT cell line derived from thyroid cancer and Ba/F3 cells transformed by various RET mutants, and has a stronger inhibition effect than selective RET inhibitor LOXO-292. In addition, the compound can block cellular RET autophosphorylation and downstream pathways, and can significantly induce TT cell death.

Abstract: Disclosed is a method for preparing hydrogen-rich fuel gas, including adding aluminum smelting waste residues into medium strong acid and soaking for 2-4 h, filtering and baking an obtained precipitate at 300-400° C. for 3-6 h to obtain pre-treated aluminum smelting waste residues; adding the waste residues into weak acid and performing ultrasonic treatment, performing centrifugal separation on an aluminum ash solution, baking for 3-6 h at a constant temperature of 400-500° C. in an air atmosphere, and naturally cooling to room temperature to obtain a cracking catalyst; uniformly mixing the cracking catalyst and biomass with a mass ratio of 1:1 and adding into a first-stage pyrolyzing furnace under N2 atmosphere, and heating from room temperature to 500-900° C. to obtain first-stage pyrolysis gas; and entering the first-stage pyrolysis gas into a second-stage pyrolyzing furnace for secondary catalytic cracking, so as to obtain hydrogen-rich fuel gas.

Abstract: The present invention relates to Map4K1 inhibitors of formula (I) (I), wherein A, E, G, Q, R1, R2 and R4 have the same meaning as defined in the description, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients.

Abstract: The present disclosure relates to compounds, and to their pharmaceutical compositions, that inhibit dipeptidyl peptidase IV (DPP4). The compounds selectively promote the proliferation of alveolar type 2 cells (AEC2s) and are useful in therapeutic methods of treating diseases whose etiology, for example, derives from epithelial degeneration and maladaptive remodeling, such as pulmonary diseases like idiopathic pulmonary fibrosis (IPF), acute respiratory distress syndrome (ARDS), and infant respiratory distress syndromes (IRDS).

Abstract: Provided are compounds having a tetradentate structure of that are useful as emitters in OLED applications.

Abstract: The present invention relates to a crystalline form and/or maleate, phosphate, L-tartrate, and adipate of the compound represented by the structural formula I, and various crystalline forms of various salt forms, and preparation methods and applications thereof.

Abstract: This disclosure provides a method for treating a subject afflicted with a tumor or a cancer, wherein the method comprises administering to the subject therapeutically effective amounts of an anti-TIM3 antibody, alone or in combination with an inhibitor of the PD-1 signaling pathway (e.g., anti-PD-1 antibody). In some embodiments, the antibody is administered as a flat dose or a weight-based dose.

Abstract: Provided are pyrimidine aromatic ring compounds. Specifically provided is a compound as represented by formula (II) or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed herein are antibodies that bind specifically to CD47 and have optimized functional and safety properties.

Abstract: The present disclosure relates generally to 1,2-azaborines and methods of making the same.